16^th International Conference and Exhibition on Pharmaceutical Formulations July 26-27, 2018 Rome, Italy

Dr Joël Richard is currently Senior Vice President, Peptides in IPSEN (France). He is globally leading all the pharmaceutical development activities of both injectable and oral peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinology and Neurology. Dr Richard has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several previous global senior positions in various Biotech and Pharma companies, such as: - Vice President, Drug Product Development in Ipsen (France) (2008-2011), - Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008), - Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004), - COO at Mainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems (1999-2001). Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials & Colloidal Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1994).

In the last 20 years, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields: polymers, colloids and interfaces, drug delivery, biodegradable microspheres, microencapsulation, supercritical fluids, protein formulations and post-translational modifications, nanoparticles, sustained-release formulations . . . He is the author of more than 120 international communications and 53 patent families.

Dr Joël Richard is currently Senior Vice President, Peptides in IPSEN (France). He is globally leading all the pharmaceutical development activities of both injectable and oral peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinology and Neurology. Dr Richard has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several previous global senior positions in various Biotech and Pharma companies, such as: - Vice President, Drug Product Development in Ipsen (France) (2008-2011), - Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008), - Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004), - COO at Mainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems (1999-2001). Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials & Colloidal Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1994).

In the last 20 years, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields: polymers, colloids and interfaces, drug delivery, biodegradable microspheres, microencapsulation, supercritical fluids, protein formulations and post-translational modifications, nanoparticles, sustained-release formulations . . . He is the author of more than 120 international communications and 53 patent families.

The Dr. Hugo Solana Goya is Doctor in Animal Science. Studied at the Faculty of Veterinary Sciences in National University of Central Buenos Aires UNCPBA (Argentina). Is Veterinarian since 1982 and PhD since 2000. Since 2007 is Director of the Laboratory of Cellular and Molecular Biology of FCV-UNCPBA in the area of Molecular Parasitology (Resistance Anthelmintic).

Cellular Biology, Molecular Biology, Parasitology, metabolism, xenobiotics, gene expression, anthelmintic resistance

will be uploaded soon..

will be uploaded soon..

Prof. Dr. Christopher Brown, Ph.D., D.Sc., CC, AOE, FRS is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He is an American analytical and organic chemist, who pioneered a number of discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose. His contributions include the discovery of the anomeric effect and the development of general methodologies for the synthesis of saccharides still employed in the area of Nucleic Acids Chemistry. He was a fellow of the American Chemical Society (ACS) and also the Royal Society of Chemistry (England), and a recipient of the prestigious Albert Einstein World Award of Science and Wolf Prize in Chemistry. Furthermore, he is currently Dean of the Faculty of Chemistry at California South University (CSU), Irvine, California, USA.

will be updated soon...

Prof. Dr. Carol Thomson, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Genetics, Virology and Immunology at California South University (CSU), Irvine, California, USA. He is a British scientist, who along with Qui-Lim Choo, George Kuo and Daniel W. Bradley, co-discovered Hepatitis B in 1989. He also co-discovered the Hepatitis D genome in 1986. The discovery of Hepatitis B led to the rapid development of diagnostic reagents to detect HCV in blood supplies which has reduced the risk of acquiring HCV through blood transfusion from one in three to about one in two million. It is estimated that antibody testing has prevented at least 40,000 new infections per year in the US alone and many more worldwide.

Prof. Dr. Carol Thomson is currently America Excellence Research Chair in Virology and Li Ka Shing Professor of Virology at the California South University (CSU) where he is also Director of the Li Ka Shing Applied Virology Institute.

Dr. A. Q. Rana, Director, Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre; Founding & Former Editor-in-chief, Journal of Parkinsonism and RLS; Founder & Former Chair, World Parkinson's Program; is one of the Organizing Committee Members for the 4th International Conference on Parkinson’s Disease and Movement Disorders (Parkinsons Disease 2017) which is held during November 27- 28, 2017 at Atlanta, USA. Dr. Rana completed his neurology residency at the New Jersey Neurosciences Institute, USA, where he trained under Dr. Arthur S. Walters, a world renowned neurologist. For further training in the field of Parkinson's disease and Movement Disorders Dr. Rana undertook a clinical fellowship at the University of Ottawa, Canada. Dr.Rana published extensively in the field of Parkinson's disease, Movement disease and Neurology. Dr. Rana was honored with the Wayne Hening Award for his research on Parkinson's disease and Restless Legs Syndrome. He was also awarded an honorary fellowship of the Royal College of Physicians (FRCP) of the United Kingdom. Dr. Rana developed many educational programs for Parkinson's disease. He is the founder of The World Parkinson's Education Program which was started in the year 2008. Dr. Rana's objectives for the World Parkinson's Education Program were enhancing knowledge by imparting education about various aspects of Parkinson’s disease. Parkinson's TEAM RANA initiative to raise awareness of Parkinson's disease was also started in various countries.

Dr. A. Q. Rana's research interests include non-motor symptoms of Parkinson’s disease.